구조모아 (StructureMoa)항암 chemical structure spider web
방문BeOne Medicines
분석
큐레이션 브리핑
경쟁 포지션: BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row.
기전. Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
PD-1
Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy
US, EU, CN
Approved
tevimbra · tislelizumab · Tevimbra · BGB-A317 · tislelizumab-jsgr
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG4 monoclonal antibody
Fc-engineered to reduce FcγR binding and antibody-dependent macrophage phagocytosis of T cells
Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row.
구조화 데이터
Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row.
Antigen-presentation loss, alternate checkpoints, immunosuppressive TME.
Humanized IgG4 monoclonal antibody
PD-1 · PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera.
Immune-mediated AEs of the PD-1 class; infusion reactions
BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row.
1L/2L esophageal squamous carcinoma and gastric/GEJ adenocarcinoma per earlier US labels; 1L HER2+ GEA with Ziihera + chemo
1L–2L gastroesophageal, regimen-dependent
IV
150 mg q2w, 200 mg q3w, 300 mg q4w, or 400 mg q6w
HERIZON-GEA-01 OS 26.4 mo in the tislelizumab-containing triplet vs 19.2 mo trastuzumab-chemo
Immune-mediated AEs of the PD-1 class; infusion reactions
BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row.
Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance.
CD8+ reinvigoration in PD-1-high tumors.
PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera.
Antigen-presentation loss, alternate checkpoints, immunosuppressive TME.
구조화 데이터
Human
~20 days class range
OS/PFS; radiographic response
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (esophageal squamous cell carcinoma)
APPROVAL · 2024년 3월
FDA approval (gastric/GEJ adenocarcinoma)
APPROVAL · 2024년 12월
FDA approval (1L HER2+ GEA with zanidatamab)
APPROVAL · 2026년 8월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
BeOne Medicines
분석
큐레이션 브리핑
경쟁 포지션: BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row.
기전. Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
PD-1
Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy
US, EU, CN
Approved
tevimbra · tislelizumab · Tevimbra · BGB-A317 · tislelizumab-jsgr
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG4 monoclonal antibody
Fc-engineered to reduce FcγR binding and antibody-dependent macrophage phagocytosis of T cells
Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row.
구조화 데이터
Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row.
Antigen-presentation loss, alternate checkpoints, immunosuppressive TME.
Humanized IgG4 monoclonal antibody
PD-1 · PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera.
Immune-mediated AEs of the PD-1 class; infusion reactions
BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row.
1L/2L esophageal squamous carcinoma and gastric/GEJ adenocarcinoma per earlier US labels; 1L HER2+ GEA with Ziihera + chemo
1L–2L gastroesophageal, regimen-dependent
IV
150 mg q2w, 200 mg q3w, 300 mg q4w, or 400 mg q6w
HERIZON-GEA-01 OS 26.4 mo in the tislelizumab-containing triplet vs 19.2 mo trastuzumab-chemo
Immune-mediated AEs of the PD-1 class; infusion reactions
BeOne PD-1 with a China-heavy development history; the US HER2+ GEA triplet is the catalog reason to keep it next to Ziihera, not next to Keytruda's pan-tumor row.
Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance.
CD8+ reinvigoration in PD-1-high tumors.
PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera.
Antigen-presentation loss, alternate checkpoints, immunosuppressive TME.
구조화 데이터
Human
~20 days class range
OS/PFS; radiographic response
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (esophageal squamous cell carcinoma)
APPROVAL · 2024년 3월
FDA approval (gastric/GEJ adenocarcinoma)
APPROVAL · 2024년 12월
FDA approval (1L HER2+ GEA with zanidatamab)
APPROVAL · 2026년 8월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.